.Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XA03_Iodine131iOmburtamab.Iodine131iOmburtamab .Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XA03_Iodine131iOmburtamab.Iodine131iOmburtamab| name: | Iodine131iOmburtamab | |
| ATC code: | V10XA03 | route: | intraventricular |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 0.15 | L |
| clearance: | 0.005 | L/hr |
| other parameters in model implementation | ||
Iodine (131I) omburtamab is a radiolabeled monoclonal antibody targeting B7-H3 (CD276) used as a radioimmunoconjugate in the treatment of central nervous system/leptomeningeal metastasis from neuroblastoma. It delivers targeted radiotherapy to tumors expressing B7-H3. As of 2024, it has been investigated in clinical trials and received an FDA Complete Response Letter and is not widely approved.
Estimated pharmacokinetic parameters for typical pediatric or adolescent neuroblastoma patients (median age 5–8 years) after intraventricular administration.